Business Description
![Bolt Biotherapeutics Inc Bolt Biotherapeutics Inc logo](https://static.gurufocus.com/logos/0C0000C1RY.png?14)
Bolt Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US0977021049
Share Class Description:
FRA:6LP: Ordinary SharesDescription
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.67 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -0.27 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -3.96 | |||||
Beneish M-Score | -2.19 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 209.7 | |||||
3-Year EBITDA Growth Rate | -8.8 | |||||
3-Year EPS without NRI Growth Rate | -6 | |||||
3-Year FCF Growth Rate | -5.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 17.51 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.86 | |||||
9-Day RSI | 43.61 | |||||
14-Day RSI | 39.64 | |||||
6-1 Month Momentum % | -30.06 | |||||
12-1 Month Momentum % | -41.92 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.68 | |||||
Quick Ratio | 5.68 | |||||
Cash Ratio | 5.46 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.2 | |||||
Shareholder Yield % | 7.25 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -661.19 | |||||
Net Margin % | -556.59 | |||||
FCF Margin % | -557.6 | |||||
ROE % | -48.86 | |||||
ROA % | -36.02 | |||||
ROIC % | -113.97 | |||||
ROC (Joel Greenblatt) % | -297.86 | |||||
ROCE % | -47.68 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.45 | |||||
PB Ratio | 0.27 | |||||
Price-to-Tangible-Book | 0.27 | |||||
EV-to-EBIT | 0.59 | |||||
EV-to-EBITDA | 0.6 | |||||
EV-to-Revenue | -3.87 | |||||
EV-to-FCF | 0.7 | |||||
Price-to-Net-Current-Asset-Value | 0.5 | |||||
Price-to-Net-Cash | 0.53 | |||||
Earnings Yield (Greenblatt) % | 169.49 | |||||
FCF Yield % | -225.96 |